+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Next-generation Sequencing Services Market by Type, Technology, Application, & End User - Forecast to 2028

  • ID: 4849287
  • Report
  • August 2021
  • Region: Global
  • 190 Pages
  • Meticulous Market Research Pvt. Ltd.
Global Next-generation Sequencing Services Market by Type (Targeted Sequencing, Exome, RNA-Seq, ChIP Sequencing), Technology (Sequencing by Synthesis, Nanopore, SMRT), Application (Clinical Diagnosis, Biomarker Discovery), and End User - Forecast to 2028



The next-generation sequencing services market is expected to grow at a CAGR of 20.4% from 2021 to 2028 to reach $14.1 billion by 2028.

Following a thorough secondary and primary research and in-depth analysis of the market scenario, the report discusses key industry drivers, restraints, challenges, and opportunities.

The growth of this market is mainly attributed to the reducing cost of NGS procedures, the development and approval of new targeted therapies, rising prevalence of cancer, partnerships between NGS service providers and pharmaceutical companies, high cost of sequencing infrastructure, and technological advancements in NGS. In addition, advancements in sequencing data analytics and the increasing applications of NGS in cancer and agri-genomics research are expected to offer significant growth opportunities for NGS service providers.

However, the availability of alternative technologies, lack of skilled professionals for sample preparation and analysis, and actionable mutations for precision medicine may restrain the growth of the NGS services market. Moreover, regulatory & standardization concerns in diagnostic testing and the ethical issues & costs related to non-invasive prenatal genetic testing are major challenges for the growth of this market.

Based on type, the global NGS services market is segmented into targeted sequencing services, whole-genome sequencing services, RNA sequencing services, exome sequencing services, de novo sequencing services, ChIP sequencing services, methyl sequencing services, and other NGS services. In 2021, the targeted sequencing services segment is estimated to account for the largest share of the global NGS services market. The large share of this segment can be attributed to the relatively lower cost, faster turnaround time, and accurate, easy-to-interpret results of targeted sequencing in the study of disease-related genes.

Based on technology, the global NGS services market is segmented into sequencing by synthesis (SBS), ion semiconductor sequencing (IOS), single-molecule real-time sequencing (SMRT), nanopore sequencing, and other NGS technologies. In 2021, the sequencing by synthesis (SBS) segment is estimated to account for the largest share of the global NGS services market. This large share of this segment is attributed to its highest yield of error-free throughput, base call value above Q30, and higher accuracy in DNA sequencing compared to other sequencing technologies available in the market.

Based on application, the global NGS services market is segmented into biomarker discovery, diagnostics, drug discovery, agriculture & animal research, and other applications. In 2021, the diagnostics segment is estimated to account for the largest share of the global NGS services market. This segment's large share is mainly attributed to the significant use of NGS services in cancer diagnostics globally and improvements in NGS-based oncology and non-invasive prenatal tests (NIPT). Growing emphasis on utilizing NGS in cancer research fuels the growth of this market.

Based on end user, the global NGS services market is segmented into hospitals & clinics, pharmaceutical & biotechnology companies, academic & research institutes, and other end users. In 2021, the hospitals & clinics segment is estimated to account for the largest share of the global NGS services market. The largest share of this segment is attributed to factors such as high capital requirements for building in-house NGS capabilities in hospitals & clinics, the rising prevalence of cancer and other chronic diseases, the growing demand for advanced medical treatments, and the rising number of biomarker-based therapies.

An in-depth analysis of the geographical scenario of the next-generation sequencing services market provides detailed qualitative and quantitative insights about the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. North America is expected to command the largest share of the global next-generation sequencing services market in 2021, followed by Europe and Asia-Pacific.

Key companies operating in the global next-generation sequencing services market are Illumina, Inc. (U.S.), QIAGEN N.V. (Netherland), PerkinElmer, Inc. (U.S.), Eurofins Scientific S.E. (Luxembourg), Macrogen, Inc. (South Korea), LGC Limited (U.K.), GENEWIZ, Inc. (U.S.), Beijing Genomics Institute (BGI) (China), SciGenom Labs Pvt. Ltd (India), MedGenome Inc. (U.S.), DNA Link, Inc. (South Korea), Otogenetics Corporation (U.S.), Novogene Co., Ltd. (China), CD Genomics (U.S.), Foundation Medicine, Inc. (U.S), and SeqLL, Inc. (U.S.).

Scope of the Report


Global Next-generation Sequencing Services Market, by Type

  • Targeted Sequencing Services
  • RNA Sequencing Services
  • De Novo Sequencing Services
  • Exome Sequencing Services
  • Chip Sequencing Services
  • Whole-genome Sequencing
  • Methyl Sequencing Services
  • Other Services

Global Next-generation Sequencing Services Market, by Technology

  • Sequencing By Synthesis (SBS)
  • Ion Semiconductor Sequencing (IOS)
  • Single-molecule Real-time Sequencing (SMRT)
  • Nanopore Sequencing
  • Other Technologies

Global Next-generation Sequencing Services Market, by Application

  • Diagnostics
  • Drug Discovery
  • Biomarker Discovery
  • Agriculture & Animal Research
  • Other Applications

Global Next-generation Sequencing Services Market, by End User

  • Hospitals & Clinics
  • Pharmaceutical & Biotechnology Companies
  • Academics & Research Institutes
  • Other End Users

Global Next-generation Sequencing Services Market, by Geography

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe (RoE)
  • Asia-Pacific (APAC)
  • Japan
  • China
  • India
  • Rest of APAC (RoAPAC)
  • Latin America
  • Middle East & Africa
Frequently Asked Questions about the Global Next-generation Sequencing Services Market

What is the estimated value of the Global Next-generation Sequencing Services Market?

The Global Next-generation Sequencing Services Market was estimated to be valued at $3.9 Billion in 2021.

What is the growth rate of the Global Next-generation Sequencing Services Market?

The growth rate of the Global Next-generation Sequencing Services Market is 20.4%, with an estimated value of $14.1 Billion by 2028.

What is the forecasted size of the Global Next-generation Sequencing Services Market?

The Global Next-generation Sequencing Services Market is estimated to be worth $14.1 Billion by 2028.

Who are the key companies in the Global Next-generation Sequencing Services Market?

Key companies in the Global Next-generation Sequencing Services Market include Illumina, Inc. (U.S.), Qiagen N.V. (Netherland), PerkinElmer, Inc. (U.S.), Eurofins Scientific S.E. (Luxembourg), Macrogen, Inc. (South Korea), LGC Limited (U.K.), GENEWIZ, Inc. (U.S.), Beijing Genomics Institute (BGI) (China), SciGenom Labs Pvt. Ltd (India), MedGenome Inc. (U.S.), DNA Link, Inc. (South Korea), Otogenetics Corporation (U.S.), Novogene Co., Ltd. (China), CD Genomics (U.S.), Foundation Medicine, Inc. (U.S), and SeqLL, Inc. (U.S.)..
Note: Product cover images may vary from those shown
1. Introduction
1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency
1.4. Key Stakeholders

2. Research Methodology
2.1. Research Process
2.2. Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research
2.3. Market Assessment
2.3.1. Market Size Estimation
2.3.1.1. Bottom-Up Approach
2.3.1.2. Top-Down Approach
2.3.1.3. Growth Forecast
2.3.2. Market Share Analysis
2.4. Assumptions for This Study
2.5. Limitations for The Study

3. Executive Summary

4. Market Insights
4.1. Market Overview
4.2. Drivers
4.2.1. Plummeting Costs of Sequencing Procedures
4.2.2. Development and Approval of New Targeted Therapies
4.2.3. Rising Prevalence of Cancer
4.2.4. Partnerships Between NGS Service Providers and Pharmaceutical Companies
4.2.5. High Cost of Sequencing Infrastructure
4.2.6. Technological Advancements in NGS
4.3. Restraints
4.3.1. Availability of Alternative Technologies
4.3.2. Lack of Skilled Professionals for Sample Preparation and Analysis
4.3.3. Low Chances of Positive Actionable Mutations for Precision Medicine
4.4. Opportunities
4.4.1. Increasing Applications in Cancer and Agri-Genomics Research
4.4.2. Advancements in Sequencing Data Analytics
4.5. Challenges
4.5.1. Regulatory & Standardization Concerns in Diagnostic Testing
4.5.2. Installation of In-House NGS Facilities in Large Hospitals and Research Institutes
4.5.3. Ethical Issues & Costs Related to Non-Invasive Prenatal Genetic Testing
4.6. The Impact of Covid-19 on The Global NGS Services Market

5. Global Next-Generation Sequencing Services Market, by Type
5.1. Introduction
5.2. Targeted Sequencing Services
5.3. RNA Sequencing Services
5.4. De Novo Sequencing Services
5.5. Exome Sequencing Services
5.6. Chip Sequencing Services
5.7. Methyl Sequencing Services
5.8. Whole-Genome Sequencing Services
5.9. Other NGS Services

6. Global Next-Generation Sequencing Services Market, by Technology
6.1. Introduction
6.2. Sequencing by Synthesis (SBS)
6.3. Ion Semiconductor Sequencing (IOS)
6.4. Single-Molecule Real-Time (SMRT) Sequencing
6.5. Nanopore Sequencing
6.6. Other NGS Technologies

7. Global Next-Generation Sequencing Services Market, by Application
7.1. Introduction
7.2. Diagnostics
7.3. Drug Discovery
7.4. Biomarker Discovery
7.5. Agriculture & Animal Research
7.6. Other Applications

8. Global Next-Generation Sequencing Services Market, by End User
8.1. Introduction
8.2. Hospitals & Clinics
8.3. Pharmaceutical & Biotechnology Companies
8.4. Academics & Research Institutes
8.5. Other End Users

9. Global NGS Services Market, by Geography
9.1. Introduction
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. U.K.
9.3.4. Italy
9.3.5. Spain
9.3.6. Rest of Europe (RoE)
9.4. Asia-Pacific
9.4.1. Japan
9.4.2. China
9.4.3. India
9.4.4. Rest of Asia-Pacific (RoAPAC)
9.5. Latin America
9.6. Middle East & Africa

10. Competitive Landscape
10.1. Introduction
10.2. Key Growth Strategies
10.3. Competitive Benchmarking
10.4. Market Share Analysis (2020)
10.4.1. Eurofins Scientific S.E.
10.4.2. Illumina, Inc.
10.4.3. Perkinelmer, Inc.
10.4.4. GENEWIZ, Inc.
10.4.5. Foundation Medicine, Inc. (Subsidiary of F. Hoffmann-La Roche AG)

11. Company Profiles
11.1. Illumina, Inc.
11.1.1. Business Overview
11.1.2. Financial Overview
11.1.3. Service Portfolio
11.1.4. Strategic Developments
11.2. QIAGEN N.V.
11.2.1. Business Overview
11.2.2. Financial Overview
11.2.3. Service Portfolio
11.3. PerkinElmer, Inc.
11.3.1. Business Overview
11.3.2. Financial Overview
11.3.3. Service Portfolio
11.4. Eurofins Scientific S.E.
11.4.1. Business Overview
11.4.2. Financial Overview
11.4.3. Service Portfolio
11.4.4. Strategic Developments
11.5. Macrogen, Inc.
11.5.1. Company Overview
11.5.2. Financial Overview
11.5.3. Service Portfolio
11.5.4. Strategic Developments
11.6. LGC Limited
11.6.1. Business Overview
11.6.2. Financial Overview
11.6.3. Service Portfolio
11.6.4. Strategic Developments
11.7. GENEWIZ, Inc.
11.7.1. Business Overview
11.7.2. Financial Overview
11.7.3. Service Portfolio
11.7.4. Strategic Developments
11.8. Beijing Genomics Institute (BGI)
11.8.1. Business Overview
11.8.2. Service Portfolio
11.8.3. Strategic Developments
11.9. Scigenom Labs Pvt., Ltd.
11.9.1. Business Overview
11.9.2. Service Portfolio
11.10. Medgenome Inc.
11.10.1. Business Overview
11.10.2. Service Portfolio
11.10.3. Strategic Developments
11.11. DNA Link, Inc.
11.11.1. Business Overview
11.11.2. Service Portfolio
11.12. Otogenetics Corporation
11.12.1. Business Overview
11.12.2. Service Portfolio
11.13. Novogene Co., Ltd.
11.13.1. Business Overview
11.13.2. Service Portfolio
11.13.3. Strategic Developments
11.14. CD Genomics
11.14.1. Business Overview
11.14.2. Service Portfolio
11.14.3. Strategic Developments
11.15. SeqLL Inc.
11.15.1. Business Overview
11.15.2. Financial Overview
11.15.3. Service Portfolio
11.16. Foundation Medicine, Inc. (Subsidiary of F. Hoffmann-La Roche AG)
11.16.1. Business Overview
11.16.2. Financial Overview
11.16.3. Service Portfolio
11.16.4. Strategic Developments

12. Appendix
12.1. Questionnaire
12.2. Available Customization
Note: Product cover images may vary from those shown

Loading
LOADING...

Illumina, Inc. (U.S.), Qiagen N.V. (Netherland), PerkinElmer, Inc. (U.S.), Eurofins Scientific S.E. (Luxembourg), Macrogen, Inc. (South Korea), LGC Limited (U.K.), GENEWIZ, Inc. (U.S.), Beijing Genomics Institute (BGI) (China), SciGenom Labs Pvt. Ltd (India), MedGenome Inc. (U.S.), DNA Link, Inc. (South Korea), Otogenetics Corporation (U.S.), Novogene Co., Ltd. (China), CD Genomics (U.S.), Foundation Medicine, Inc. (U.S), and SeqLL, Inc. (U.S.).
Note: Product cover images may vary from those shown